Relmada Therapeutics

Q2 FY2026 EarningsQ2 FY26 results beat consensus on bottom-line metrics, with a GAAP net loss of $12.9M vs. the $19.9M expected and EPS of -$0.11 vs. the -$0.20 expected. The loss narrowed significantly on a per-share basis due to a higher share count following recent capital raises. R&D expenses surged 198% YoY to $8.4M as the company prepares for Phase 3 RESCUE trials for NDV-01. The cash balance of $217.7M provides a strong runway through 2029, supporting the upcoming IND filings for NDV-01 and sepranolone expected by year-end 2026.